Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Beyond the Dose: Introducing LOGOS for Dosage Regimen Design in Therapeutics

View ORCID ProfileVangelis D. Karalis
doi: https://doi.org/10.64898/2026.10.17.26365797
Vangelis D. Karalis
1Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15784 Athens, Greece
2Institute of Applied and Computational Mathematics, Foundations for Research and Technology Hellas (FORTH), 70013, Heraklion, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vangelis D. Karalis
  • For correspondence: vkaralis{at}pharm.uoa.gr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The aim of this study was to develop a framework for assessing the incremental value of decisions on drug amount, timing, input structure, cessation and restart. The LOGOS (Longitudinal Optimization of Global Outcomes and Strategies) approach combines matched nested regimen classes, mechanism-specific benchmarks and evidence requirements in a single longitudinal comparison. Thus, the contribution of additional regimen freedom is assessed separately from improvements due to different resources, constraints or evaluation horizons. Nested feasible classes have nondecreasing objective suprema, whereas a strict gain requires a feasible witness above a valid bound for the smaller class. The approach is illustrated through analytical examples of periodic smoothing, matched desensitization, relaxed exposure allocation, finite-course loading and safety after cessation. In a normalized finite Emax model, integrated benefit increased from 0.629606 for three equal boluses to 0.672945 after optimization of amounts, 0.677043 for an amount-and-time candidate and 0.679553 for a globally certified loading-maintenance-coast solution. The adjacent observed gains were 6.88%, 0.61% and 0.37%, respectively, and all schedules satisfied the full-tail injury bound. In addition, a periodic factorial example separated response curvature from a joint recovery and repair process, including a null case and results dependent on feasibility constraints. The LOGOS framework allows assessment of whether additional regimen flexibility improves benefit, provides no added value or restores feasibility. These dimensionless examples support conditional mathematical and model-based conclusions; clinical superiority and safe restart in patients have not been established.

Competing Interest Statement

The authors have declared no competing interest.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

https://github.com/vkaralis/LOGOS-theory-general

Data availability

The dimensionless examples are specified by the equations and parameter values reported in this paper. No patient observations were studied. The associated Zenodo record provides a persistent identifier for citation and access (DOI: 10.5281/zenodo.23402665): https://doi.org/10.5281/zenodo.23402665.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 19, 2026.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Beyond the Dose: Introducing LOGOS for Dosage Regimen Design in Therapeutics
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Beyond the Dose: Introducing LOGOS for Dosage Regimen Design in Therapeutics
Vangelis D. Karalis
medRxiv 2026.10.17.26365797; doi: https://doi.org/10.64898/2026.10.17.26365797
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Beyond the Dose: Introducing LOGOS for Dosage Regimen Design in Therapeutics
Vangelis D. Karalis
medRxiv 2026.10.17.26365797; doi: https://doi.org/10.64898/2026.10.17.26365797

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (638)
  • Allergy and Immunology (919)
  • Anesthesia (352)
  • Cardiovascular Medicine (5016)
  • Dentistry and Oral Medicine (496)
  • Dermatology (429)
  • Emergency Medicine (679)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1695)
  • Epidemiology (16282)
  • Forensic Medicine (36)
  • Gastroenterology (1242)
  • Genetic and Genomic Medicine (7289)
  • Geriatric Medicine (753)
  • Health Economics (1094)
  • Health Informatics (5303)
  • Health Policy (1474)
  • Health Systems and Quality Improvement (1836)
  • Hematology (599)
  • HIV/AIDS (1383)
  • Infectious Diseases (except HIV/AIDS) (16501)
  • Intensive Care and Critical Care Medicine (1203)
  • Medical Education (701)
  • Medical Ethics (157)
  • Nephrology (754)
  • Neurology (7616)
  • Nursing (380)
  • Nutrition (1132)
  • Obstetrics and Gynecology (1296)
  • Occupational and Environmental Health (1041)
  • Oncology (3751)
  • Ophthalmology (1096)
  • Orthopedics (411)
  • Otolaryngology (466)
  • Pain Medicine (502)
  • Palliative Medicine (143)
  • Pathology (721)
  • Pediatrics (1864)
  • Pharmacology and Therapeutics (757)
  • Primary Care Research (786)
  • Psychiatry and Clinical Psychology (6149)
  • Public and Global Health (10009)
  • Radiology and Imaging (2539)
  • Rehabilitation Medicine and Physical Therapy (1524)
  • Respiratory Medicine (1271)
  • Rheumatology (663)
  • Sexual and Reproductive Health (805)
  • Sports Medicine (598)
  • Surgery (806)
  • Toxicology (109)
  • Transplantation (320)
  • Urology (308)